MedTrace Logo

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

NCT01706510 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2015-05-05

No results posted yet for this study

Summary

Assess the pharmacodynamic effect of ticagrelor vs. Clopidogrel in American Indian patients with stable coronary artery disease.

Conditions

Interventions

DRUG

Ticagrelor

Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days

DRUG

Clopidogrel

Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Rapid City Regional Hospital, Inc

    lead OTHER

Principal Investigators

  • James S Walder, MD · Rapid City Regional Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-03-31
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01706510 on ClinicalTrials.gov